Payment overview · 2025
General Payments
$401.76
18 reported records · 11 companies
Healthcare provider profile · identity verified
Hilbert Zeballos, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · APOPKA, FL · NPI 1700807526
Verified facts
What the public records show
CMS Open Payments records show Hilbert Zeballos, M.D. received $401.76 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.07 | 19.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $66.93 | 16.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.76 | 13.1% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.11 | 11.2% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $27.17 | 6.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.93 | 6.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.09 | 6.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.96 | 5.7% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $20.40 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.01 | 4.7% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $17.33 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.76 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.76 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $45.11 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Merck Sharp & Dohme LLC | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
160 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 269 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 36 |
| Gabapentin | Gabapentin | 200 | 34 |
| Furosemide | Furosemide | 175 | 35 |
| Eliquis | Apixaban | 160 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 16 |
| Xarelto | Rivaroxaban | 136 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 116 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 17 |
| Potassium Chloride | Potassium Chloride | 108 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 25 |
| Carvedilol | Carvedilol | 96 | 13 |
| Lisinopril | Lisinopril | 95 | 22 |
| Metformin Hcl | Metformin Hcl | 92 | 14 |
| Memantine Hcl | Memantine Hcl | 89 | 17 |
| Donepezil Hcl | Donepezil Hcl | 84 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 14 |
| Levetiracetam | Levetiracetam | 78 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 13 |
| Trazodone Hcl | Trazodone Hcl | 72 | 17 |
| Sertraline Hcl | Sertraline Hcl | 70 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 17 |
| Allopurinol | Allopurinol | 66 | suppressed |
| Baclofen | Baclofen | 66 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 17 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 19 |
| Divalproex Sodium | Divalproex Sodium | 51 | 14 |
| Levofloxacin | Levofloxacin | 51 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Levemir | Insulin Detemir | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 23 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Omeprazole | Omeprazole | 24 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Acetic Acid | Acetic Acid | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | 14 |
| Risperidone | Risperidone | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nevanac | Nepafenac | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.76 · 18 records | AstraZeneca Pharmaceuticals LP | ADCETRIS, BESREMI, DANZITEN, ELREXFIO, ENHERTU, JEMPERLI, KEYTRUDA, LYNPARZA, NINLARO, Nubeqa, Optune Lua (NovoTTF-200T), Orserdu, REBLOZYL, Stivarga, ULTOMIRIS, Vitrakvi, ZEJULA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error